A nurse is caring for a client with HIV/AIDS who has a CD4+ count of 50 cells/mm³ and is experiencing persistent oral thrush despite antifungal treatment. The client reports difficulty swallowing and decreased appetite. What is the most appropriate nursing intervention?

Persistent oral thrush with dysphagia in an immunocompromised patient (CD4+ 50 cells/mm³) suggests possible esophageal candidiasis. The nurse should collaborate to evaluate and adjust antifungal therapy. Other options address only symptomatic relief without managing the underlying opportunistic infection.

Understanding the Clinical Presentation

The client’s CD4+ count of 50 cells/mm³ indicates severe immunosuppression, classifying this as advanced HIV disease (AHD). At this level, the body lacks sufficient immune surveillance to contain opportunistic infections. The presence of persistent oral thrush despite antifungal treatment, combined with new-onset dysphagia (difficulty swallowing) and decreased appetite, signals a high probability that the fungal infection has extended beyond the oral cavity into the esophagus. This progression from localized to systemic or deeper infection is a hallmark of AHD-related opportunistic infections ^[3]. In patients with HIV, esophageal candidiasis is one of the most common causes of infectious esophagitis and frequently presents with odynophagia or dysphagia when oral lesions are refractory to topical therapy ^[4].

Why Other Interventions Are Insufficient

Performing oral care every 2 hours (Option 1) is a supportive measure that helps maintain mucosal integrity and may reduce the superficial fungal load in the oropharynx. However, it cannot reach or resolve an established infection within the esophageal lumen. Similarly, advising the client to eat only cold, pureed foods (Option 2) is a comfort-focused intervention that may lessen pain during oral intake, but it does not address the underlying pathophysiology of an invasive fungal infection. Applying a topical anesthetic gel (Option 4) before meals may temporarily facilitate swallowing by numbing the mucosa, but this symptomatic approach carries risks, including aspiration if pharyngeal sensation is overly blunted, and it fails to treat the source of the dysphagia. In the context of a severely immunocompromised client with a CD4+ count of 50 cells/mm³, delaying systemic or targeted treatment for a deep-seated infection can lead to further complications, including esophageal ulceration or dissemination .

Rationale for Collaborative Evaluation and Therapy Adjustment

The most appropriate intervention is to collaborate with the healthcare provider to evaluate for esophageal candidiasis and adjust antifungal therapy (Option 3). The refractory nature of the oral thrush suggests the current antifungal agent may be inadequate in dose, route, or spectrum. Oral topical agents, such as nystatin suspension, are ineffective against esophageal disease because they do not deliver therapeutic concentrations to the distal esophagus. Systemic antifungal therapy, typically with fluconazole, is required for esophageal candidiasis, and in cases of azole resistance, alternative agents such as echinocandins or amphotericin B may be necessary. Endoscopic evaluation may be warranted to confirm the diagnosis, as other opportunistic infections—including cytomegalovirus (CMV), herpes simplex virus (HSV), or even rare entities like histoplasmosis—can produce similar symptoms and endoscopic findings in patients with AHD ^[4]. Furthermore, unusual histopathologic findings, such as esophageal parakeratosis, can mimic malignancy and co-occur with Candida, complicating the clinical picture and reinforcing the need for direct visualization and biopsy when symptoms persist . The nurse’s role is to recognize that persistent oropharyngeal symptoms with new esophageal complaints represent a treatment failure requiring escalation of care, not merely intensified comfort measures.